AC Immune (ACIU) Projected to Post Quarterly Earnings on Wednesday

AC Immune (NASDAQ:ACIU) is anticipated to issue its Q1 2026 results before the market opens on Wednesday, April 29th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $0.3290 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, April 29, 2026 at 12:30 PM ET.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Friday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. The business had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.14 million. AC Immune had a negative net margin of 1,977.71% and a negative return on equity of 103.15%. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

AC Immune Stock Performance

NASDAQ:ACIU opened at $2.84 on Monday. The company has a market capitalization of $289.03 million, a PE ratio of -3.38 and a beta of 1.63. The company has a 50 day simple moving average of $2.92 and a two-hundred day simple moving average of $3.10. AC Immune has a fifty-two week low of $1.51 and a fifty-two week high of $4.00.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ACIU. Jefferies Financial Group reissued a “buy” rating and set a $7.00 target price on shares of AC Immune in a research report on Friday, March 13th. Wall Street Zen raised shares of AC Immune from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. BTIG Research reissued a “buy” rating and set a $8.00 target price on shares of AC Immune in a research report on Monday, March 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research report on Monday, April 20th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, AC Immune currently has an average rating of “Hold” and an average target price of $9.00.

Institutional Trading of AC Immune

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ACIU. EFG International AG acquired a new stake in shares of AC Immune during the 4th quarter worth approximately $41,000. Private Advisor Group LLC acquired a new stake in shares of AC Immune during the 3rd quarter worth approximately $48,000. Sei Investments Co. acquired a new stake in shares of AC Immune during the 2nd quarter worth approximately $51,000. Goldman Sachs Group Inc. grew its position in shares of AC Immune by 46.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after buying an additional 5,920 shares during the period. Finally, Susquehanna International Group LLP acquired a new stake in shares of AC Immune during the 3rd quarter worth approximately $63,000. Institutional investors and hedge funds own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.